21 May 2018

Contents

Editorial

• 21 May 2018: vol 19 no 9: DTG Alert and BHIVA/BASHH reports

Treatment alerts

• Potential safety signal for dolutegravir from the time of conception

Conference reports

• Fourth Joint Conference of BHIVA/BASHH (4th BHIVA/BASHH)

• Low PEP and PrEP awareness among trans people in London and their partners

• Low awareness of PrEP in BME communities in Leeds but high interest in use

• Younger people living with HIV more likely to have a positive self image

• Zero or negligible risks of HIV, HBV or HCV transmission by biting or spitting

• UK-CAB community representation on guideline panels and research studies

Treatment access

• Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries

• Generic manufacturers from South Africa and South Korea join Medicine Patent Pool (MPP)

• WHO releases first list for essential diagnostics

• Campaign forces Government U-turn on linking NHS data to immigration service

Pregnancy

• Dolutegravir in pregnancy: early data reassuring but ongoing surveillance is still essential

Paediatric care

• FDA guidance for developing paediatric ARVs: online for comment (2018)

OIs, coinfections and complications

• US study tracks kidney transplant results from HIV positive donors

Basic science and immunology

• New online animation of HIV lifecycle

Other news

• St Stephen’s AIDS Trust to close after 30 years of HIV research

PDFs

• 21 May 2018: vol 19 no 9